Candel Therapeutics (CADL) announced the appointment of Bali Pulendran, Ph.D. to Candel’s Research Advisory Board, RAB. Dr. Pulendran is the Violetta L. Horton Professor at Stanford University School of Medicine and Director of the Institute for Immunity, Transplantation and Infection at Stanford University and a Fellow at ChEM-H
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics: Hold Rating Amid Promising Developments and Financial Uncertainty
- Candel Therapeutics Secures $130M Loan for Trials
- Candel Therapeutics enters into $130M term loan facility
- Candel Therapeutics announces interim data from phase 1b CAN-3110 trial
- Trinity Capital provides $130M in growth capital to Candel Therapeutics